LifeStance HEALTH

Q3 2022 Earnings Presentation

November 8, 2022



Forward-Looking Statements

DISCLAIMERS

Cautionary Note Regarding Forward-Looking Statements

This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which LifeStance operates, including statements regarding full-year and fourth quarter guidance and management's related assumptions, future results of operations and financial position of LifeStance, which are subject to known and unknown uncertainties and contingencies outside of LifeStance's control and which are largely based on our current expectations and projections about future events and financial trends that we believe may affect LifeStance's financial condition, results of operations, business strategy, and prospects. LifeStance's actual results, events, or circumstances may differ materially from these statements. Forward-looking statements include all statements that are not historical facts. Words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, factors and assumptions, including, among other things: we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with affiliated practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; the impact of health care reform legislation and other changes in the healthcare industry and in health care spending on us is currently unknown, but may harm our business; if our or our vendors' security measures fail or are breached and unauthorized access to our employees' patients' or partners' data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; actual or anticipated changes or fluctuations in our results of operations; our existing indebtedness could adversely affect our business and growth prospects; and the other factors set forth in our filings with the Securities and Exchange Commission.

The forward-looking statements, together with statements relating to our past performance, should not be regarded as a reliable indicator of our future performance. We undertake no obligation to update any forward-looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect new information or the occurrence of unanticipated events, except as may be required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future mergers, dispositions, joint ventures, or investments.

Use of Non-GAAP Financial Measures

In addition to financial measures presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation includes certain non-GAAP financial measures, including Center Margin and Adjusted EBITDA. These non-GAAP measures are in addition to, and not a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. GAAP. The non-GAAP financial measures used by LifeStance may differ from the non-GAAP financial measures used by other companies. A reconciliation of these measures to the most directly comparable U.S. GAAP measure is included in the Appendix to these slides or as otherwise described in these slides.

Market and Industry Data

This presentation also contains information regarding our market and industry that is derived from third-party research and publications. This information involves a number of assumptions and limitations. Forecasts, assumptions, expectations, beliefs, estimates and projections involve risk and uncertainties and are subject to change based on various factors.

LifeStance at a Glance*

Mission-driven

Increasing access to personalized, trusted and affordable mental healthcare

Building the Nation's Leading Outpatient Mental Health Platform

$820M | TTM revenues[1]

5,431 | Clinicians

32 | States

~600 | Centers

10+ | Integrated care programs

Hybrid | Virtual and in-person care model

*Note: Unless otherwise stated, data is as of September 30, 2022; [1]Trailing twelve months

Q3 Financial Highlights

- **Q3 Revenue of $217.6 million increased 25% year-over-year**
- **Q3 Center Margin of $60.3 million**, or 27.7% as a percentage of revenue
- **Q3 Adjusted EBITDA of $15.4 million**, or 7.1% as a percentage of revenue
- Ended Q3 with a **cash position of $90.3 million**; for the nine months ended September 30, 2022, provided **$16.9 million cash flow from operations**, including **$5.7 million** during Q3

Note: See reconciliation of GAAP to non-GAAP measures in the Appendix to this presentation.

Q3 2022 Strategy & Key Developments

- **Total clinicians of 5,431, +24% Y/Y**; 205 net clinician adds in Q3
- **Completed 3 acquisitions in Q3,** bringing the total since inception to 86
- **Opened 13 de novo centers in Q3** to support the company's differentiated hybrid model offering both in-person and virtual care
- **Continued to deploy proprietary online booking and intake experience ("OBIE")** across the country, which is now live in 14 states
- **Ken Burdick appointed company's new Chief Executive Officer and Chairman**, effective September 7; Burdick is an accomplished industry veteran with over 40 years of healthcare experience and a track record of driving profitable growth
- **Michael Lester**, who served as the company's founding Chief Executive Officer and Chairman since 2017 **retired in September**; Lester will continue to serve as a Strategic Advisor to the company
- **Danish Qureshi appointed to President**, in addition to his role as Chief Operating Officer
- Subsequent to the end of Q3, **J. Michael Bruff appointed to new role as Business Transformation Officer**, effective November 10; **David Bourdon** will join LifeStance and **succeed Bruff as Chief Financial Officer**

Q3 2022 Results

Clinicians



Revenue (in $M)



Center Margin (in $M)

Center Margin (% of total revenue)

29.9% 27.7%

Adjusted EBITDA (in $M)

Adj. EBITDA (% of total revenue)

6.2% 7.1%

LifeStance HEALTH

Note: See reconciliation of GAAP to non-GAAP measures in the Appendix to this presentation.

Quarterly Trends

Clinicians



Revenue (in $M)



Center Margin (in $M)



Center Margin (% of total revenue)

29.9%	28.5%	26.7%	28.5%	27.7%

Adjusted EBITDA (in $M)



Adj. EBITDA (% of total revenue)

6.2%	6.0%	6.2%	7.0%	7.1%

LifeStance HEALTH

Note: See reconciliation of GAAP to non-GAAP measures in the Appendix to this presentation.

Balance Sheet, Cash Flow & Capital Allocation

Balance Sheet & Cash Flow

$90M
Cash and Cash Equivalents

$212M
Net Long-term Debt

$17M
Operating Cash Flow (YTD)

$69M
Capital Expenditures (YTD)

Capital Allocation

De Novos

Highly efficient model with predictable profitability

307 de novos opened since inception, including **13** in Q3

Acquisitions

Disciplined investments to drive growth

86 acquisitions since inception, including **3** in Q3

Continue to deploy capital in a disciplined manner to grow our clinician base and expand our footprint

LifeStance HEALTH

2022 Guidance

(All $ in M)	FY 2022		Q4 2022
Revenue	$845 – $850	• Guidance range lowered due to lower visit volume expectations	$215 – $220
Center Margin	$229 – $232	• Guidance range lowered due to lower revenue expectations and higher than expected costs associated with employee health benefits program	$55 – $58
Adj. EBITDA	$50 – $53	• See drivers above	$7.5 – $10.5

Planning Assumptions

- Assumes **~90 de novo center openings**, which were weighted heavily toward the first half of the year
- Assumes **M&A spend of ~$60M**
- Assumes no further COVID-related impacts or changes in the labor market environment

Note: Center Margin and Adjusted EBITDA anticipated for fourth quarter of 2022 and full year 2022 are calculated in a manner consistent with the historical presentation of these measures in the Appendix to this presentation. Reconciliation for the forward-looking fourth quarter of 2022 and full year 2022 Center Margin and Adjusted EBITDA guidance is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

LifeStance HEALTH

Appendix

Quarterly Statements of Operations and Comprehensive Loss

($M)	2022			2021			
	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Total Revenue	**$217.6**	**$209.5**	**$203.1**	**$190.1**	**$173.8**	**$160.5**	**$143.1**
Operating expenses							
Center costs, excluding depreciation and amortization	157.3	149.7	148.9	135.8	121.8	109.3	99.1
General and administrative	81.2	103.6	103.4	152.7	162.9	85.5	32.7
Depreciation and amortization	17.9	16.7	15.7	15.4	13.8	12.8	12.2
Loss from operations	**(38.8)**	**(60.5)**	**(64.9)**	**(113.8)**	**(124.7)**	**(47.0)**	**(0.9)**
Other income (expense)							
Gain (loss) on remeasurement of contingent consideration	1.2	(0.2)	(0.4)	(1.1)	(0.9)	(0.3)	(0.3)
Transaction costs	(0.2)	(0.0)	(0.3)	(0.1)	(0.1)	(2.0)	(1.5)
Interest expense	(4.2)	(7.1)	(3.4)	(3.6)	(3.5)	(23.2)	(8.6)
Other expense	(0.1)	—	—	(0.0)	—	(1.4)	(0.1)
Total other expense	(3.4)	(7.3)	(4.2)	(4.9)	(4.5)	(26.8)	(10.6)
Loss before taxes	**(42.2)**	**(67.8)**	**(69.0)**	**(118.6)**	**(129.2)**	**(73.8)**	**(11.4)**
Income tax benefit (provision)	4.4	(0.9)	6.7	10.6	8.8	3.8	2.8
Net loss	**($37.9)**	**($68.7)**	**($62.3)**	**($108.0)**	**($120.5)**	**($70.0)**	**($8.7)**
Other comprehensive income							
Unrealized gains on cash flow hedge, net of tax	3.2	–	–	–	–	–	–
Comprehensive loss	**($34.7)**	**($68.7)**	**($62.3)**	**($108.0)**	**($120.5)**	**($70.0)**	**($8.7)**

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited.

LifeStance HEALTH

GAAP to Non-GAAP Reconciliations – Center Margin

($M)	2022			2021			
	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Loss from operations	**($38.8)**	**($60.5)**	**($64.9)**	**($113.8)**	**($124.7)**	**($47.0)**	**($0.9)**
Adjusted for:							
Depreciation and amortization	17.9	16.7	15.7	15.4	13.8	12.8	12.2
General and administrative [1]	81.2	103.6	103.4	152.7	162.9	85.5	32.7
Center Margin	**$60.3**	**$59.8**	**$54.2**	**$54.2**	**$52.1**	**$51.2**	**$44.0**

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited.

1 - Represents salaries, wages and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock and unit-based compensation for all employees.

LifeStance HEALTH

GAAP to Non-GAAP Reconciliations – Adjusted EBITDA

	2022			2021			
($M)	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Net loss	**($37.9)**	**($68.7)**	**($62.3)**	**($108.0)**	**($120.5)**	**($70.0)**	**($8.7)**
Adjusted for:							
Interest expense	4.2	7.1	3.4	3.6	3.5	23.2	8.6
Depreciation and amortization	17.9	16.7	15.7	15.4	13.8	12.8	12.2
Income tax (benefit) provision	(4.4)	0.9	(6.7)	(10.6)	(8.8)	(3.8)	(2.8)
(Gain) loss on remeasurement of contingent consideration	(1.2)	0.2	0.4	1.1	0.9	0.3	0.3
Stock and unit-based compensation	34.9	57.5	59.9	108.6	120.7	29.5	0.6
Management fees (1)	—	—	—	—	—	1.4	0.1
Loss on disposal of assets	0.1	—	—	0.0	—	—	—
Transaction costs (2)	0.2	0.0	0.3	0.1	0.1	2.0	1.5
Offering related costs (3)	—	—	—	—	—	8.7	—
Endowment to the LifeStance Health Foundation	—	—	—	—	—	10.0	—
CEO transition costs	0.5	—	—	—	—	—	—
Litigation costs (4)	0.1	—	—	—	—	—	—
Other expenses (5)	0.9	0.9	1.8	1.1	0.9	0.5	0.6
Adjusted EBITDA	**$15.4**	**$14.6**	**$12.5**	**$11.4**	**$10.7**	**$14.5**	**$12.6**

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited.

1 - Represents management fees paid to certain of our executive officers and affiliates of our principal stockholders pursuant to the management services agreement entered into in connection with the acquisition of LifeStance by affiliates of TPG Inc. (the "TPG Acquisition"). During the year ended December 31, 2021, the management services agreement terminated in connection with the IPO and we were required to pay a one-time fee of $1.2 million to such parties.
2 - Primarily includes capital markets advisory, consulting, accounting and legal expenses related to our acquisitions.
3 - Primarily includes non-recurring incremental professional services, such as accounting and legal, and directors' and officers' insurance incurred in connection with the IPO.
4 - Litigation costs include only those costs which are considered non-recurring and outside of the ordinary course of business based on the following considerations, which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) the complexity of the case, (iii) the nature of the remedy(ies) sought, including the size of any monetary damages sought, (iv) the counterparty involved, and (v) our overall litigation strategy.
5 - Primarily includes costs incurred to consummate or integrate acquired centers, certain of which are wholly-owned and certain of which are affiliated practices, in addition to the compensation paid to former owners of acquired centers and related expenses that are not reflective of the ongoing operating expenses of our centers. Acquired center integration and other are components of general and administrative expenses included in our unaudited consolidated statements operations and comprehensive loss. Former owner fees is a component of center costs, excluding depreciation and amortization included in our unaudited consolidated statements of operations and comprehensive loss.

Quarterly Non-GAAP Financial Metrics

($M)	2022 Q3	2022 Q2	2022 Q1	2021 Q4	2021 Q3	2021 Q2	2021 Q1
Key Metrics							
Clinicians	**5,431**	**5,226**	**4,989**	**4,790**	**4,375**	**3,975**	**3,301**
Total Revenue	**$217.6**	**$209.5**	**$203.1**	**$190.1**	**$173.8**	**$160.5**	**$143.1**
Center costs, excluding depreciation and amortization	157.3	149.7	148.9	135.8	121.8	109.3	99.1
Center Margin (Non-GAAP)	**$60.3**	**$59.8**	**$54.2**	**$54.2**	**$52.1**	**$51.2**	**$44.0**
% Margin	27.7%	28.5%	26.7%	28.5%	*29.9%*	*31.9%*	*30.7%*
General and administrative	81.2	103.6	103.4	152.7	162.9	85.5	32.7
Depreciation and amortization	17.9	16.7	15.7	15.4	13.8	12.8	12.2
Loss from operations	**(38.8)**	**(60.5)**	**(64.9)**	**(113.8)**	**(124.7)**	**(47.0)**	**(0.9)**
Other income (expenses)							
Other income (expenses)	1.0	(8.3)	2.5	5.7	4.2	(23.0)	(7.8)
Net loss	**($37.9)**	**($68.7)**	**($62.3)**	**($108.0)**	**($120.5)**	**($70.0)**	**($8.7)**
Other comprehensive income							
Unrealized gains on cash flow hedge, net of tax	3.2	—	—	—	—	—	—
Comprehensive loss	**($34.7)**	**($68.7)**	**($62.3)**	**($108.0)**	**($120.5)**	**($70.0)**	**($8.7)**
Adjusted EBITDA build							
Net loss	(37.9)	(68.7)	(62.3)	(108.0)	(120.5)	(70.0)	(8.7)
Interest expense	4.2	7.1	3.4	3.6	3.5	23.2	8.6
Depreciation and amortization	17.9	16.7	15.7	15.4	13.8	12.8	12.2
Income tax (benefit) provision	(4.4)	0.9	(6.7)	(10.6)	(8.8)	(3.8)	(2.8)
(Gain) loss on remeasurement of contingent consideration	(1.2)	0.2	0.4	1.1	0.9	0.3	0.3
Stock and unit-based compensation	34.9	57.5	59.9	108.6	120.7	29.5	0.6
Management fees	—	—	—	—	—	1.4	0.1
Loss on disposal of assets	0.1	—	—	0.0	—	—	—
Transaction costs	0.2	0.0	0.3	0.1	0.1	2.0	1.5
Offering related costs	—	—	—	—	—	8.7	—
Endowment to the LifeStance Health Foundation	—	—	—	—	—	10.0	—
CEO transition expenses	0.5	—	—	—	—	—	—
Litigation costs	0.1	—	—	—	—	—	—
Other expenses	0.9	0.9	1.8	1.1	0.9	0.5	0.6
Adjusted EBITDA (Non-GAAP)	**$15.4**	**$14.6**	**$12.5**	**$11.4**	**$10.7**	**$14.5**	**$12.6**
% Margin	7.1%	7.0%	6.2%	6.0%	*6.2%*	*9.1%*	*8.8%*

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited.

LifeStance HEALTH

Quarterly Balance Sheets

($M)	2022 Q3	2022 Q2	2022 Q1	2021 Q4	2021 Q3	2021 Q2	2021 Q1
Cash and cash equivalents	90.3	96.7	114.0	148.0	212.1	276.2	39.5
Patient accounts receivable, net	113.3	99.7	95.0	76.1	70.1	60.1	47.8
Prepaid expenses and other current assets	49.0	47.9	54.3	42.4	46.1	27.8	22.3
Total current assets	**252.6**	**244.3**	**263.3**	**266.5**	**328.3**	**364.1**	**109.6**
Property and equipment, net	193.4	190.7	170.9	152.2	115.1	91.8	70.8
Intangible assets, net	272.5	282.1	291.2	300.4	308.0	316.5	323.3
Goodwill	1,249.8	1,243.7	1,229.3	1,204.5	1,160.0	1,138.7	1,099.7
Other noncurrent assets	11.4	7.9	3.7	3.5	3.4	3.3	2.9
Total noncurrent assets	**1,727.1**	**1,724.4**	**1,695.1**	**1,660.6**	**1,586.4**	**1,550.4**	**1,496.7**
Total assets	**$1,979.7**	**$1,968.7**	**$1,958.4**	**$1,927.1**	**$1,914.8**	**$1,914.4**	**$1,606.3**
Accounts payable	7.9	12.9	15.1	14.2	3.1	10.0	5.9
Accrued payroll expenses	61.6	61.2	73.2	60.0	57.6	50.4	45.4
Other accrued expenses	29.3	26.2	21.8	26.5	28.3	38.8	25.7
Current portion of contingent consideration	10.8	9.0	13.5	14.1	14.0	10.9	14.9
Other current liabilities	2.6	2.2	2.0	2.0	2.2	2.6	4.9
Total current liabilities	**112.3**	**111.5**	**125.6**	**116.8**	**105.2**	**112.6**	**96.8**
Long-term debt, net	212.0	203.4	177.4	157.4	157.5	157.1	387.3
Other noncurrent liabilities	67.0	64.5	57.5	50.3	22.9	15.7	14.2
Contingent consideration, net of current portion	1.5	3.7	1.1	3.3	3.1	3.2	1.1
Deferred tax liability, net	55.4	54.3	54.3	54.3	81.2	81.2	81.2
Total noncurrent liabilities	**335.9**	**325.8**	**290.3**	**265.3**	**264.7**	**257.2**	**483.8**
Total liabilities	**$448.2**	**$437.4**	**$415.9**	**$382.1**	**$369.9**	**$369.8**	**$580.5**
Redeemable units	—	—	—	—	—	—	**71.8**
Common stock/units	3.8	3.8	3.7	3.7	3.7	3.7	1,010.5
Additional paid-in capital	2,050.5	2,015.7	1,958.2	1,898.4	1,790.2	1,669.5	2.1
Accumulated other comprehensive income	3.2	—	—	—	—	—	—
Accumulated deficit	(526.0)	(488.1)	(419.4)	(357.1)	(249.0)	(128.6)	(58.6)
Total stockholders'/members' equity	1,531.5	**1,531.3**	**1,542.5**	**1,545.0**	**1,544.9**	**1,544.6**	**954.0**
Total liabilities, redeemable units and stockholders'/members' equity	**$1,979.7**	**$1,968.7**	**$1,958.4**	**$1,927.1**	**$1,914.8**	**$1,914.4**	**$1,606.3**

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited.

LifeStance HEALTH

Statements of Cash Flows

($M)	Nine Months Ended Q3'22	Six Months Ended Q2'22	Q1'22	Nine Months Ended Q3'21	Six Months Ended Q2'21	Q1'21	2021 FY
CASH FLOWS FROM OPERATING ACTIVITIES							
Net loss	**(168.9)**	**(131.1)**	**(62.3)**	**(199.2)**	**(78.7)**	**(8.7)**	**(307.2)**
Adjustments to reconcile net loss to net cash provided by (used by) operating activities:							
Depreciation and amortization	50.3	32.4	15.7	38.8	25.0	12.2	54.1
Stock and unit-based compensation	152.2	117.4	59.9	150.8	30.1	0.6	259.4
Deferred income taxes	—	—	—	—	—	—	(26.9)
Loss on debt extinguishment	3.4	3.4	—	5.6	5.6	—	14.4
Amortization of discount and debt issue costs	1.4	0.7	0.3	1.5	1.1	0.4	1.8
(Gain) loss on remeasurement of contingent consideration	(0.6)	0.6	0.4	1.5	0.6	0.3	2.6
Loss on disposals of assets	0.1	—	—	—	—	—	—
Endowment of shares to LifeStance Health Foundation	—	—	—	9.0	9.0	—	9.0
Change in operating assets and liabilities, net of businesses acquired:							
Patient accounts receivable, net	(34.6)	(21.9)	(18.1)	(20.7)	(11.8)	(3.1)	(24.2)
Prepaid expenses and other current assets	(5.8)	(5.4)	(12.1)	(32.9)	(15.0)	(8.0)	(29.1)
Accounts payable	1.1	1.7	1.9	(4.6)	2.3	3.0	0.6
Accrued payroll expenses	(0.6)	(0.3)	12.8	15.9	9.6	7.3	15.3
Other accrued expenses	18.8	13.5	4.9	13.1	15.3	5.9	39.6
Net cash provided by (used by) operating activities	**$16.9**	**$11.1**	**$3.3**	**($21.2)**	**(7.0)**	**$9.9**	**$9.4**
CASH FLOWS FROM INVESTING ACTIVITIES							
Purchases of property and equipment	(68.9)	(53.8)	(27.9)	(55.8)	(31.8)	(11.1)	(94.5)
Acquisitions of businesses, net of cash acquired	(40.3)	(35.1)	(22.9)	(58.7)	(39.1)	(0.8)	(99.6)
Net cash used in investing activities	**($109.2)**	**($88.9)**	**($50.9)**	**($114.5)**	**($70.9)**	**($11.8)**	**($194.1)**
CASH FLOWS FROM FINANCING ACTIVITIES							
Proceeds from initial public offering, net of underwriters discounts and commissions and deferred offering costs	—	—	—	548.9	554.2	—	548.9
Payments of deferred offering costs	—	—	—	—	—	(0.3)	—
Issuance of common units to new investors	—	—	—	1.0	1.0	—	1.0
Proceeds from long-term debt, net of discount	237.5	228.0	20.0	98.8	98.8	26.2	98.8
Payments of debt issue costs	(7.3)	(7.2)	—	(2.4)	(2.4)	(1.0)	(2.4)
Payments of long-term debt	(181.2)	(181.2)	(0.3)	(311.1)	(310.7)	(0.8)	(311.4)
Prepayment for debt paydown	(1.6)	(1.6)	—	—	—	—	(8.8)
Payments of contingent consideration	(12.3)	(11.1)	(5.7)	(6.3)	(5.6)	(1.5)	(12.3)
Taxes related to net share settlement of equity awards	(0.5)	(0.5)	(0.4)	—	—	—	—
Net cash provided by financing activities	**$34.6**	**$26.4**	**$13.5**	**$329.0**	**$335.3**	**$22.6**	**$313.9**
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	**($57.7)**	**($51.3)**	**($34.0)**	**$193.3**	**$257.4**	**$20.7**	**$129.2**
Cash and Cash Equivalents - Beginning of period	148.0	148.0	148.0	18.8	18.8	18.8	18.8
CASH AND CASH EQUIVALENTS – END OF PERIOD	**$90.3**	**$96.7**	**$114.0**	**$212.1**	**$276.2**	**$39.5**	**$148.0**

Subtotals in the schedule above may not foot due to rounding. Amounts are unaudited.

LifeStance HEALTH